ArticleClinical, cosmetic and investigational dermatology2025
Additive Therapeutic Effects of Topical Sirolimus Following Oral Propranolol Therapy for Kaposiform Hemangioendothelioma.
Article in Clinical, cosmetic and investigational dermatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- A Systematic Review and Meta-Analysis of the Efficacy and Safety of Propranolol Versus Other Drugs in the Treatment of Infantile Hemangioma.Journal of cosmetic dermatology · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Kaposiform hemangioendothelioma (KHE) is a rare but aggressive vascular tumor, potentially life-threatening when associated with Kasabach-Merritt phenomenon (KMP). Oral sirolimus is effective but may cause systemic adverse effects in infants. Oral propranolol offers a safer alternative in early infancy, but its efficacy may plateau over time. Sequential topical sirolimus may enhance outcomes while minimizing systemic toxicity. Objective: To evaluate the additive therapeutic effect and safety of topical sirolimus in KHE patients with suboptimal response after oral propranolol. Methods: This retrospective study included five pediatric patients with cutaneous KHE treated at Beijing Children's Hospital from October 2018 to October 2022. All had received oral propranolol for ≥24 months and showed therapeutic plateau (tumor shrinkage ≤70%). They were subsequently treated with 0.1% topical sirolimus ointment twice daily for at least six months and followed for one year. Efficacy was assessed by Visual Analog Scale (VAS), Doppler ultrasound, and a four-grade evaluation system; safety was monitored throughout. Results: All patients showed significant improvement within 6-12 months (mean: 9.6 months), achieving Grade III or IV response. Doppler imaging revealed reduced or absent blood flow signals, and lesions nearly regressed in some cases. Symptoms such as pain and localized hyperthermia resolved, and skin appearance normalized. Two patients experienced mild local irritation; no systemic adverse effects or recurrences were observed. Conclusion: Sequential topical sirolimus following oral propranolol offers a safe and effective treatment strategy for KHE, especially after therapeutic plateau. It enhances efficacy, avoids systemic toxicity, and may accelerate lesion regression. Further large-scale studies are warranted to optimize individualized treatment protocols.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.